Company Introduction JBKLAB is a company that creates a healthy future for humanity.
At JBK Lab, our Research Institute is at the forefront of our commitment to improving the health of the nation and contributing to the development of our local communities. Through continuous investment in research and development, we strive to introduce innovative products on a global scale, focusing on herbal and crude drug preparations derived from natural substances.
- Fucoidan extract (FucoranTM): Development of individually recognized health functional food for immune function improvement (2025)
- Powerful immune activity confirmed in fucoidan polysaccharide extract.
- Evaluation of fucoidan's animal model and mechanism of action research: Increased activation of immune cells confirmed, cancer cell metastasis inhibition confirmed (joint research in progress with Professor Kwang Soon Shin of Kyunggi University)
- Development of analytical methods for indicator components / Standard specification setting and standardization research in progress
- Aronia-Alginic Acid Nanocomplex (AANC): Development of individually recognized health functional food for antioxidants (2026)
- Powerful antioxidant effect confirmed in aronia extract (ABF)
- Maintaining antioxidant activity with low molecular weight alginic acid that stabilizes ABF
- Aiming for domestic individual recognition health functional food approval after completion of domestic human application tests (2026)
- AANC
- Confirmed effect on prevention and inhibition of progression of Alzheimer's dementia (development of mild cognitive impairment treatment)
- Study on the mechanism of action of AANCP's beta-amyloid (Aβ) aggregation inhibition and removal:
-
50% of the population aged 85 develops, and currently, there are no drugs that can fundamentally treat it.
Beta-amyloid aggregation progresses gradually over 20 years, leading to severe Alzheimer's dementia
The most feared disease by the elderly. Dementia should be managed from a young age
Confirmed the effect of AANC on inhibiting the aggregation of beta-amyloid (Aβ).
- AFNC : Anticancer metastasis inhibition effect and improvement of anticancer drug side effects (development of adjuvant anticancer drugs)
-
Study on anticancer metastasis inhibition effect and mechanism of action: Cell experiment and animal model evaluation (Professor Kwang Soon Shin)
Immune enhancement effect in immune suppression model caused by anticancer drugs; animal model evaluation (outsourced to external CRO)
Synergy effect when combined with existing anticancer drugs in lung cancer: Animal model evaluation (outsourced to external CRO)
Anticancer adjuvant study in lung cancer patients: Investigator-initiated clinical trial (Respiratory Medicine Department of Chonbuk National University, Hwasun Hospital of Chonnam National University)
Fucoran™ mouse clinical model with intravenous injection: Confirmed powerful anticancer immune effect, cancer metastasis inhibition effect
- Anticancer cell inhibition effect
- Excellent anticancer cell inhibition effect in colon cancer and liver cancer cell lines without toxicity in normal cell lines when treated with AFNC
- Immune enhancement effect
- Superior immune activation through cytokines in JBK Lab's developed product, active fucoidan (Fucoran), compared to other companies' fucoidan
- Synergistic effect with anticancer drugs
- In a group treated with doxorubicin (DOX) in breast cancer mice, 3 out of 5 mice died, but none died in the group treated with both doxorubicin and AFNC PBS / DOX administration group / DOX + AFNC administration group
combined administration of
AFNC and anticancer drugs
combined administration of
AFNC and anticancer drugs
Developing therapeutics for hard-to-treat solid cancers with high unmet medical needs by fundamentally blocking cancer cells' evasion mechanisms with a synthetic lethality* strategy
Normal cell
Cancer cell
| Existing treatment | JBKLAB | |
|---|---|---|
| Dosage |  |
 |
| Cost |  |
 |
| Pain | |
|
| Convenience of outpatient visits | |
|
| Product | Abraxane (Paclitaxel) | JBK-NCE |
| Avastin (Bevacizumab) | ||
| Halaven (Eribulin) |
Development of health functional foods centered on natural substances
Product development centered on natural substance raw materials
- High-quality product development strictly managed from natural plant raw materials to finished product stages
- Differentiated product development based on proprietary base technology
Customized health functional food product development and formulation research
- Customized health functional food product development according to age, gender, and preference
- Research on functional products for improved dosage convenience
Various health functional food formulation development research
- Tablet
- Capsule
- Soft Capsule
- Syrup
- Granule
- Jelly
Development of differentiated oriental medicine formulations and general pharmaceuticals
Research on oriental medicine formulations centered on natural substances
- Differentiated product development using plant-based excipients
- Development of proprietary production processes that minimize chemical additives
- Product development applying solid formulation technology with secured production and product stability
Research on differentiated formulation technology
- Research on new formulations differentiated from released products for improved dosage convenience and compliance
1. Study on tablet size reduction
- Description : Oblong bilayer tablet (plain tablet)
- Weight : 1,780 mg
- Size : 22.5 x 8.7 x 10.5 mm
Long axis
부피15%
- Description : Oval bilayer tablet (coated tablet)
- Weight : 1,578 mg
- Size : 19.7 x 9.4 x 10.5 mm
Long axis
2. Research on fast-acting formulation technology
Ensuring rapid disintegration & dissolution for proper drug absorption
3. Research on developing various pharmaceutical formulations
- Tablet
- Mini-Tablet
- Capsule
- Granule
- Powder
- Tablet in Capsule
Development of improved new drugs and functional pharmaceuticals
Establishment of a formulation technology platform roadmap for the rapid development of technology-intensive
pharmaceuticals and research on formulation design for site-specific drug release
Formulation design according to drug absorption and release rate control by body part
Research on drug release control technology
- Fast drug effect onset and sustained drug effect maintenance technology through immediate/delayed layer design
- Multi-layer formulation technology for drug stability, target site absorption, and release time control
Research on combination drug formulations
- Formulation technology that maximizes drug effects by developing formulations containing more than two components in one formulation
 Single-layer tablet: |
Mono matrix formulation technology with two or more components uniformly mixed |
|---|---|
 Multi-layer tablet |
Technology that can secure stability by minimizing interactions between multiple drugs |
 Core tablet: |
Drug release control technology targeting different gastrointestinal sites for each component |
Key patents and certifications status
Anthocyanin complex composition and manufacturing method
Composition for the prevention and treatment of non-alcoholic fatty liver disease
Immunostimulant, immuno-oncology agent Japanese patent
Composition for the prevention of aging diseases using anthocyanin-polysaccharide complex
Manufacturing method for liposomes containing aronia extract with improved formulation stability
Use of anthocyanin-anionic polysaccharide complex
Microspheres containing anthocyanin and manufacturing method
1
Composition for inducing cellular senescence containing (R)-(-)-2,2-dimethyl-1,3-dioxolane-4-methanol as an active ingredient and method for inducing cellular senescence using the same
Domestic
10-2009-0129750
2009-12-23
2
3
Pharmaceutical composition for the prevention, improvement, or treatment of cancer containing 2,6-dichloro-4-(4-(4-hydroxycyclohexylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenol as an active ingredient
Domestic
PCT
10-2022-0054797
PCT/KR2022/006339
2022-05-03
2022-05-03
4
5
6
7
8
9
Use of anthocyanin-anionic polysaccharide complex for the prevention or treatment of type A influenza virus infection
Domestic
PCT
USA
Europe
China
Japan
10-2019-0075991
PCT/KR2020/008235
17/621,846
20832685.0
202080046672.X
2021-576649
2019-06-25
2020-06-24
2021-12-22
2021-12-28
2021-12-24
2021-12-22
10
3-(4-(piperazin-1-yl)benzamido)-1H-pyrazolopyridine derivative or its pharmaceutically acceptable salt, method for manufacturing the same, and pharmaceutical composition for the prevention or treatment of MELK-related diseases containing the same as an active ingredient
Domestic
10-2015-0146654
2015-10-21
11
N-aryl-1H-pyrazolopyridine-3-amine derivative or its pharmaceutically acceptable salt, method for manufacturing the same, and pharmaceutical composition for the prevention or treatment of MELK-related diseases containing the same as an active ingredient
Domestic
10-2015-0146653
2015-10-21
12
13
14
15
16
17
Compounds with TrkA inhibitory activity and pharmaceutical compositions for the prevention or treatment of pain containing them as active ingredients.
Domestic
PCT
USA
Japan
Europe
China
10-2018-0087092
PCT/KR2019/006648
17/261,944
2021-528310
19840528.4
201980049772.5
2018-07-26
2019-06-03
2021-01-21
2021-01-25
2021-02-02
2021-01-26
18
Compositions for the prevention and treatment of non-alcoholic fatty liver disease.
Domestic
10-2014-0070363
2014-06-10
19
Anti-diabetic compositions containing plant mixed extracts.
Domestic
10-2010-0080548
2010-08-19
20
Liquid compositions containing anthocyanin compounds and methods for their preparation.
Domestic
10-2020-0102327
2020-08-14
21
nthocyanin complexes using anionic polysaccharides, compositions containing them, and methods for their preparation.
Domestic
10-2011-0044491
2011-05-12
22
Indole derivatives or their pharmaceutically acceptable salts, methods of their preparation, and pharmaceutical compositions for the prevention or treatment of 5-HT6 receptor-related diseases containing them as active ingredients.
Domestic
10-2013-0066662
2013-06-11
23
Pharmaceutical compositions containing Chokeberry bioactive fraction C3G complex as active ingredients for the prevention and treatment of atherosclerosis and hypertension.
Domestic
10-2010-0053609
2010-06-07
24
ompositions for inducing cell aging containing phenyl 2-pyridyl ketoxime as active ingredients and methods for inducing cell aging using them.
Domestic
10-2007-0118752
2007-11-20
25
Anti-cancer radiosensitizers containing pyrazolyl pyrrolopyrimidine derivatives as active ingredients.
Domestic
10-2020-0045553
2020-04-14
26
27
28
29
30
31
Immunostimulants, immuno-oncology agents, and anti-cancer adjuvants containing anthocyanin-fucoidan complexes as active ingredients.
Domestic
PCT
China
Europe
Japan
USA
10-2018-0128919
PCT/KR2018/012849
201880083898.X
18 870 322.7
2020-543440
16/759,364
2018-10-26
2018-10-26
2020-06-24
2020-05-25
2020-04-24
2020-04-27
32
Methods for preparing liposomes containing Aronia extract with improved formulation stability.
Domestic
10-2018-0163094
2018-12-17
33
Micropheres containing anthocyanins and methods for their preparation.
Domestic
10-2019-0171922
2019-12-20
Natural drug research pipeline
| Category | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Natural health food | FucoranTM | Immune function improvement |
|
||||||||
| AANCP | Antioxidant |
|
|||||||||
| AANCP | Stomach health |
|
|||||||||
| Natural pharmaceuticals | AANCP | Dementia treatment development (mild cognitive impairment) |
|
||||||||
| AFNCP | Improvement of anticancer drug side effects |
|
|||||||||
Synthetic drug research pipeline
| Category | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Anticancer drugs | JSA-101 |
|
||||||||
| JSA-201 |
|
|||||||||
| Anti-inflammatory drugs | JSI-301 |
|
||||||||
| JSI-401 |
|
|||||||||